A comparison of Oral and Inhalant Corticosteroids in Treatment of Mild to Moderate Asthma Exacerbation in Children

Nemat Bilan, Lida Saboktakin, Masoumeh Ghasempour

Abstract


Introduction: Oral corticosteroids are the main treatment in asthma exacerbation. It has been reported that inhaled corticosteroids can be used instead of oral corticosteroids in asthma exacerbation. We aimed to evaluate the efficacy of inhaled fluticasone and oral prednisolone in children with mild to moderate asthma exacerbation. 

Materials and Methods: In this randomized clinical trial, 60 children with mild-to-moderate acute asthma exacerbation visiting emergency department were randomly assigned to receive oral prednisolone (2 mg/kg) or fluticasone spray (2 puffs every 12 hours, each puff contains 250 microgram fluticasone) using an spacer for one week. The first dose of the treatment was given in the emergency department.  Children were followed for seven days and signs and symptoms of exacerbation, as well as spirometry findings were evaluated.

Results: On the days 1 and 3, symptoms including cough, sputum and need for salbutamol during day was more improved in oral prednisolone and symptoms at night was more improved in inhaled fluticasone. Patients were almost symptom free on the seventh day. Forced expiratory volume in 1 second, forced vital capacity and forced expiratory flow rate on the seventh day were significantly better with inhaled fluticasone compared to oral prednisolone.

Conclusion: Both inhaled fluticasone and oral prednisolone improved symptoms during a week after exacerbation; however, better respiratory function in children treated with inhaled fluticasone is indicative of its further efficacy compared to oral prednisolone. Considering the low systemic effects of inhaled fluticasone, this treatment seems to be more appropriate in treatment of mild to moderate exacerbations.

 

Keywords: Asthma exacerbation; Inhaled fluticasone; Prednisolone


Full Text:

PDF

References


Martinez FD. Trends in asthma prevalence, admission rates, and asthma deaths. Respir Care. 2008;53:561-5.

Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics. 2009;123 Suppl 3:S131-45.

American Academy of Pediatrics Committee on Pediatric Emergency Medicine. Overcrowding crisis in our nation’s emergency departments: is our safety net unraveling? Pediatrics. 2004;114(3):878–888.

Stang AS, McGillivray D, Bhatt M, Colacone A, Soucy N, Léger R, et al. Markers of overcrowding in a pediatric emergency department. Acad Emerg Med. 2010;17(2):151–156.

Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-78.

Kling S1, Zar HJ, Levin ME, Green RJ, Jeena PM, Risenga SM, et al. Guideline for the management of acute asthma in children: 2013 update. S Afr Med J. 2013;103(3 Pt 3):199-207.

Mitchell EA. Consensus on acute asthma management in children: AdHoc Pediatric Group. N Z Med J. 1992; 105: 353-5.

National Asthma Education and Prevention Program. National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 2007. Vol 08-5846.

Lougheed MD, Garvey N, Chapman KR, Cicutto L, Dales R, Day AG, et al. Variations and gaps in management of acute asthma in Ontario emergency departments. Chest. 2009;135(3):724–736.

Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane. Database. Syst Rev. 2001;(1):CD002178.

Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics. 2003;112:382-397.

Scarfone RJ, Friedlaender E. Corticosteroids in acute asthma: past, present, and future. Pediatr Emerg Care. 2003;19:355-361.

Butler K, Cooper WO. Adherence of pediatric asthma patients with oral corticosteroid prescriptions following pediatric emergency department visit or hospitalization. Pediatr Emerg Care. 2004;20:730-735.

Gamble J, Stevenson M, McClean E, Heaney LG. The Prevalence of Non-adherence in Difficult Asthma. Am J Respir Crit Care Med. 2009;180:817-22.

Beeraka SS, Natarajan K, Patil R, Manne RK, Prathi VS, Kolaparthi VS. Clinical and radiological assessment of effects of long-term corticosteroid therapy on oral health. Dent Res J (Isfahan). 2013;10(5):666-73.

Tse SM, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG; Childhood Asthma Management Program Research Group. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J Allergy Clin Immunol. 2012;130(1):53-60.e4.

Busse W, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, et al. Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial. Thorax. 2012;67:35–41.

Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 2010;95(5):365–370.

National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin. Immunol. 2007;120(5 Suppl):S94–138.

Raissy HH, Blake K. As Needed Use of Inhaled Corticosteroids for Management of Mild Persistent Asthma in Children. Pediatr Allergy Immuno Pulmonol. 2011;24(4):231-233.

Bleecker ER1, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012;109(5):353-358.e4.

Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000;343:689–694.

Nakanishi AK, Klasner AK, Rubin BK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest. 2003;124:790–794.

Manjra AI, Price J, Lenney W, Hughes S, Barnacle H. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med. 2000;94(12):1206-14.

Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: A review of the evidence. Respir Med. 2007;101(4):685-95.

Razi CH, Turktas I, Bakirtas A. Comparison of single 2000-microg dose treatment vs. sequential repeated-dose 500-microg treatments with nebulized budesonide in acute asthma exacerbations. Ann Allergy Asthma Immunol. 2008;100:370–376.

Ververeli K, Chipps B. Oral corticosteroid–sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann. Allergy. Asthma Immunol. 2004;92:512–522.

Nuhoglu Y, Bahceciler NN, Barlan IB, Mujdat Basaran M. The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children. Ann Allergy Asthma Immunol. 2001;86:318–322.

Schuh S, Dick PT, Stephens D, Hartley M, Khaikin S, Rodrigues L, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics. 2006;118(2):644-50.

Zemek R, Plint A, Osmond MH, Kovesi T, Correll R, Perri N, et al. Triage nurse initiation of corticosteroids in pediatric asthma is associated with improved emergency department efficiency. Pediatrics. 2012;129(4):671-80.

Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest. 2000; 117:440–446.

Schramm CM, Carroll CL. Advances in treating acute asthma exacerbations in children. Curr Opin Pediatr. 2009;21(3):326-32.

Abdullah AK, Khan S. Evidence‑based selection of inhaled corticosteroid for treatment of chronic asthma. J Asthma. 2007;44:1‑12.

Singas E, Karpel JP. Profile of ciclesonide for the maintenance treatment of asthma. Ther Clin Risk Manag. 2011;7:351-8.

FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, et al. Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax. 2004; 59:550–556.

Volovitz B, Nussinovitch M, Finkelstein Y, Harel L, Varsano I. Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. Clin Pediatr (Phila). 2001; 40:79–86.

Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet. 2004; 363:271–275.

Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med. 1998; 5:209–213.

Singhi SC, Banerjee S, Nanjundaswamy HM. Inhaled budesonide in acute asthma. J Paediatr Child Health. 1999; 35:483–487.

Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized Budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999; 88:835–840.

Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol. 1998;102:605–9.

Milani GKM, Nelson A, Filho R, Riedi CA, Figueiredo BC. Nebulised budesonide to treat acute asthma in children. J Pediatr. 2004;80:106–12.

Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med. 2005;171:1231–1236.

Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006;130:1301–1311.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine